Pharma & biotech news
Syndax: $83.3M revenue, $67.5M R&D, quarter to Sep 2026
Syndax filed a 10-Q with the SEC on 2 Nov 2026 covering the period ending 30 Sep 2026: revenue $83.3 million (83,298,000 USD) and R&D spend $67.5 million (67,481,000 USD), which is 81.0% of that revenue; net income $-49,433,000 (-49,433,000 USD).